Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

aTYR PHARMA (ATYR) Profit After Tax (2019 - 2025)

Historic Profit After Tax for aTYR PHARMA (ATYR) over the last 6 years, with Q3 2025 value amounting to -$25.7 million.

  • aTYR PHARMA's Profit After Tax fell 4915.71% to -$25.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$75.1 million, marking a year-over-year decrease of 1774.71%. This contributed to the annual value of -$64.0 million for FY2024, which is 2703.73% down from last year.
  • aTYR PHARMA's Profit After Tax amounted to -$25.7 million in Q3 2025, which was down 4915.71% from -$19.5 million recorded in Q2 2025.
  • In the past 5 years, aTYR PHARMA's Profit After Tax ranged from a high of -$7.5 million in Q4 2022 and a low of -$25.7 million during Q3 2025
  • Over the past 4 years, aTYR PHARMA's median Profit After Tax value was -$14.8 million (recorded in 2023), while the average stood at -$14.8 million.
  • Examining YoY changes over the last 5 years, aTYR PHARMA's Profit After Tax showed a top increase of 1436.77% in 2023 and a maximum decrease of 9621.16% in 2023.
  • Over the past 4 years, aTYR PHARMA's Profit After Tax (Quarter) stood at -$7.5 million in 2022, then plummeted by 96.21% to -$14.8 million in 2023, then decreased by 1.4% to -$15.0 million in 2024, then tumbled by 72.02% to -$25.7 million in 2025.
  • Its last three reported values are -$25.7 million in Q3 2025, -$19.5 million for Q2 2025, and -$14.9 million during Q1 2025.